Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 04, 2022

SELL
$12.54 - $46.93 $2.48 Million - $9.29 Million
-197,946 Reduced 98.97%
2,054 $33,000
Q4 2021

Jan 25, 2022

BUY
$45.28 - $74.5 $9.06 Million - $14.9 Million
200,000 New
200,000 $9.48 Million

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $130M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track Sage Partners LTD Portfolio

Follow Sage Partners LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sage Partners LTD, based on Form 13F filings with the SEC.

News

Stay updated on Sage Partners LTD with notifications on news.